Workers at Boeing are expected to vote Wednesday on a tentative deal reached over the weekend to end a five-week strike that analysts said has cost the aircraft maker more than $1 billion.

The tentative agreement between Boeing and the International Association of Machinists and Aerospace Workers, reached with the help of federal mediators, includes wage increases of 35% over four years. Company and union officials said the pact also includes a higher signing bonus of $7,000, higher company 401(k) contributions, and guaranteed minimum payouts in an annual bonus program.

“We look forward to our employees voting on the negotiated proposal,” Boeing said in a statement. A statement from the union said the tentative pact “warrants presenting to the members” and is worthy of workers’ consideration.

More than 30,000 workers at Boeing plants near Seattle and Portland, Oregon, went on strike Sept. 13, after machinists rejected an offer that included a 25% wage increase. A later company offer with a higher proposed raise was also rejected.

Analysts at firms such as JP Morgan and Jefferies estimated wage hikes in the proposed new contract will raise Boeing’s annual costs by more than $1 billion. Ratings firm S&P Global estimated the strike itself has already cost the company more than $1 billion.

Earlier this month, Boeing CEO Kelly Ortberg announced plans to cut 10% of the company’s workforce as the Arlington, Virginia-based firm looks to reduce costs. The company also plans to discontinue production of its 767 craft after orders are fulfilled in 2027.

Takeda Pharmaceuticals plans to cut nearly 80 jobs in Massachusetts by March 25, the latest in a series of nationwide biotech workforce and real estate pullbacks this year as the industry reacts to slowing demand and shifting research priorities.

The latest state notification filings showed Tokyo-based Takeda planned to cut 45 jobs at its Cambridge location and 34 at its Lexington office in Massachusetts. The reductions will bring Takeda’s 2024 total to more than 1,300 worldwide, after earlier announced cuts totaling about 860 in Massachusetts and the closing of a San Diego hub that employed 324.

Takeda officials cited an ongoing restructuring of operations that led to the latest job reductions. A company statement said “difficult choices” will be required as the company enacts its initiatives, and specific changes “will look different across individual teams and will be phased according to unique business needs.”

Brokers and industry analysts have reported slowing real estate demand across numerous life science hubs, including Boston, San Francisco and San Diego. Vacancies have been rising over the past year as space is placed back on the market for subleasing, particularly among small- and mid-sized tenants, and as some developers struggle to fill newly built facilities.